ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.58
0.00%
US Tech 100
21,286.80
-0.09%
S&P 500
6,118.71
0.00%
US Dollar vs CAD
1.43367
-0.30%
Bitcoin
105,259.25
1.25%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Abivax SA (ABVX)

  7. Abivax SA (ABVX) News

ABVX

Abivax (ABVX)

Abivax SA
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ABVX
DateTimeSourceHeadlineSymbolCompany
01/23/20253:05PMGlobeNewswire Inc.Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual CongressNASDAQ:ABVXAbivax SA
01/10/20258:04AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ABVXAbivax SA
01/09/202510:35AMGlobeNewswire Inc.Abivax Achieves Key Milestone in Phase 3 ABTECT Trial EnrollmentNASDAQ:ABVXAbivax SA
12/23/20244:14PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ABVXAbivax SA
12/23/20243:05PMGlobeNewswire Inc.Abivax Announces a Change to the Composition of its Board of DirectorsNASDAQ:ABVXAbivax SA
11/26/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ABVXAbivax SA
11/19/20243:43PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ABVXAbivax SA
11/19/20243:30PMGlobeNewswire Inc.Abivax Establishes an At-the-Market (ATM) Program on NasdaqNASDAQ:ABVXAbivax SA
11/19/20243:02PMEdgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:ABVXAbivax SA
11/14/20243:01PMGlobeNewswire Inc.Abivax presents third quarter 2024 key financial informationNASDAQ:ABVXAbivax SA
11/14/20243:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ABVXAbivax SA
11/13/20243:01PMGlobeNewswire Inc.Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to AbivaxNASDAQ:ABVXAbivax SA
10/07/20243:01PMGlobeNewswire Inc.Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene RegulationNASDAQ:ABVXAbivax SA
10/03/20243:18PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ABVXAbivax SA
10/03/20243:01PMGlobeNewswire Inc.Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s DiseaseNASDAQ:ABVXAbivax SA
10/03/20245:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ABVXAbivax SA
10/03/20241:31AMGlobeNewswire Inc.Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label MaintenanceNASDAQ:ABVXAbivax SA
09/26/20245:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ABVXAbivax SA
09/26/20241:30AMGlobeNewswire Inc.Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024NASDAQ:ABVXAbivax SA
09/25/20243:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ABVXAbivax SA
09/25/20243:01PMGlobeNewswire Inc.Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse ModelNASDAQ:ABVXAbivax SA
09/09/20243:27PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ABVXAbivax SA
09/09/20243:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ABVXAbivax SA
09/09/20243:01PMGlobeNewswire Inc.Abivax presents first-half 2024 financial resultsNASDAQ:ABVXAbivax SA
09/09/20245:09AMIH Market NewsU.S. Futures Rise Amid Inflation Report Anticipation; Oil Prices Climb on Hurricane Threat and Supply ConcernsNASDAQ:ABVXAbivax SA
08/06/20241:30AMGlobeNewswire Inc.Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment MilestoneNASDAQ:ABVXAbivax SA
07/15/20243:00PMGlobeNewswire Inc.Abivax Provides Operational and Key Program UpdateNASDAQ:ABVXAbivax SA
06/04/20243:26PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ABVXAbivax SA
06/04/20243:10PMGlobeNewswire Inc.Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General MeetingNASDAQ:ABVXAbivax SA
05/07/20243:26PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ABVXAbivax SA
 Showing the most relevant articles for your search:NASDAQ:ABVX

Your Recent History

NASDAQ
AMRN
Amarin
USOTC
TGLO
TheGlobe com (PK)
USOTC
BMXI
Brookmount Explorations (PK)
USOTC
AZRH
Azure (PK)
NASDAQ
TNXP
Tonix Pharmaceuticals
NASDAQ
LWLG
Lightwave Logic
USOTC
NWBO
Northwest Biotherapeutics (QB)
USOTC
ASII
Accredited Solutions (PK)
USOTC
RITE
MineralRite (PK)
USOTC
UMAV
UAV Corpoation (PK)
USOTC
AXXA
Exxe (PK)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
RDGL
Vivos (QB)
USOTC
HMBL
HUMBL (PK)
NYSE
IONQ
IonQ
USOTC
TWOH
Two Hands (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads